Published :
Tables : 49
Figures : 44
Category : Healthcare
No. of Pages : 226
Report Code : HC-1190
Cell Viability Assays Market is estimated to value over CAGR of over 7.5% by 2028 end. Cell viability assays are technologies that are used for determining the cell strength in response to any tested drug. They are generally tested on a tissue, cell or an organ. Cell viability looks for the cells to identify any inorganic reaction which they aren’t supposed to follow and scale this reaction to mark its viability. This plays an important role in all forms of cell culture. Cell viability forms the basis of an assay to look out for drug effectiveness or cell viability with multiple combined particles and it also offers different characteristics of cell health to the user. Cell viability assay is primarily performed in all in vitro and pharmaceutical studies due to increased applications of cell viability assays for drug screening. A large number of local manufacturers have expanded their cell viability assay kits product portfolio to determine effects in cell growth and cell death for the sake of clinical research and this has increased the demand for cell viability assays thus aiding the cell viability assays market size proliferation. Key market players include: Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, GE Healthcare, Danaher Corporation, Becton, Dickinson and Company, Promega Corporation, Biotium, Abcam PLC, Creative Bioarray, Biotek Instruments, Perkinelmer. Cell Viability Assays Market Segmentation: By Product • Consumables o Reagents o Assay Kits • Tetrazolium Reduction Assay Kits o Mtt Assay Kits o Other Tetrazolium Assay Kits • Resazurin Cell Viability Assay Kits • Calcein-Am Cell Viability Assay Kits • Other Assay Kits o Microplates • Instruments o Automated Cell Counters o Flow Cytometers o Spectrophometers o Cell Imaging & Analysis Systems By Cell Type Human Cells Animal Cells Microbial Cells By Application Drug Discovery and Development Basic Research Stem Cell Research Clinical and Diagnostic Applications Other Applications By End User Pharmaceutical & Biotechnology Companies Academic & Research Institutes Hospital & Diagnostic Laboratories Other End Users By Region North America Europe Asia Pacific Latin America Middle East & Africa Competitive Landscape: Tier 1 players- established companies in the market with a major market share Tier 2 players Emerging players which are growing rapidly New Entrants FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global cell viability assays market by product, by cell type, by application, by end user and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Latin America and Middle East & Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Cell viability assays are technologies that are used for determining the cell strength in response to any tested drug. They are generally tested on a tissue, cell or an organ. Cell viability looks for the cells to identify any inorganic reaction which they aren’t supposed to follow and scale this reaction to mark its viability. This plays an important role in all forms of cell culture. Cell viability forms the basis of an assay to look out for drug effectiveness or cell viability with multiple combined particles and it also offers different characteristics of cell health to the user.
Cell viability assay is primarily performed in all in vitro and pharmaceutical studies due to increased applications of cell viability assays for drug screening. A large number of local manufacturers have expanded their cell viability assay kits product portfolio to determine effects in cell growth and cell death for the sake of clinical research and this has increased the demand for cell viability assays thus aiding the cell viability assays market size proliferation.
Key market players include: Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, GE Healthcare, Danaher Corporation, Becton, Dickinson and Company, Promega Corporation, Biotium, Abcam PLC, Creative Bioarray, Biotek Instruments, Perkinelmer.
Cell Viability Assays Market Segmentation:
By Product • Consumables o Reagents o Assay Kits • Tetrazolium Reduction Assay Kits o Mtt Assay Kits o Other Tetrazolium Assay Kits • Resazurin Cell Viability Assay Kits • Calcein-Am Cell Viability Assay Kits • Other Assay Kits o Microplates • Instruments o Automated Cell Counters o Flow Cytometers o Spectrophometers o Cell Imaging & Analysis Systems
By Cell Type
By Application
By End User
By Region
Competitive Landscape:
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Cell Viability Assays Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Cell Viability Assays Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Cell Viability Assays Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Cell Viability Assays Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1 Consumables 7.1.1. Reagents 7.1.2. Assay Kits 7.1.2.1. Tetrazolium Reduction Assay Kits 7.1.2.1.1. Mtt Assay Kits 7.1.2.1.2. Other Tetrazolium Assay Kits 7.1.2.2. Resazurin Cell Viability Assay Kits 7.1.2.3. Calcein-Am Cell Viability Assay Kits 7.1.2.4. Other Assay Kits 7.1.3. Microplates 7.2. Instruments 7.2.1. Automated Cell Counters 7.2.2. Flow Cytometers 7.2.3. Spectrophometers 7.2.4. Cell Imaging & Analysis Systems 8. Global Cell Viability Assays Market, By Cell Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Human Cells 8.2. Animal Cells 8.3. Microbial Cells 9. Global Cell Viability Assays Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Drug Discovery and Development 9.2. Basic Research 9.3. Stem Cell Research 9.4. Clinical and Diagnostic Applications 9.5. Other Applications 10. Global Cell Viability Assays Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Pharmaceutical & Biotechnology Companies 10.2. Academic & Research Institutes 10.3. Hospital & Diagnostic Laboratories 10.4. Other End Users 11. North America Cell Viability Assays Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028 12. Latin America Cell Viability Assays Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028 13. Europe Cell Viability Assays Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028 14. Asia Pacific Cell Viability Assays Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. Thermo Fisher Scientific 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Merck KGaA 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Bio-Rad Laboratories 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. GE Healthcare 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Danaher Corporation 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Becton, Dickinson and Company 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Promega Corporation 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Biotium 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Abcam PLC 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Creative Bioarray 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Biotek Instruments 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Perkinelmer 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Global Cell Viability Assays Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Cell Viability Assays Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Cell Viability Assays Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Global Cell Viability Assays Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1 Consumables 7.1.1. Reagents 7.1.2. Assay Kits 7.1.2.1. Tetrazolium Reduction Assay Kits 7.1.2.1.1. Mtt Assay Kits 7.1.2.1.2. Other Tetrazolium Assay Kits 7.1.2.2. Resazurin Cell Viability Assay Kits 7.1.2.3. Calcein-Am Cell Viability Assay Kits 7.1.2.4. Other Assay Kits 7.1.3. Microplates 7.2. Instruments 7.2.1. Automated Cell Counters 7.2.2. Flow Cytometers 7.2.3. Spectrophometers 7.2.4. Cell Imaging & Analysis Systems
8. Global Cell Viability Assays Market, By Cell Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Human Cells 8.2. Animal Cells 8.3. Microbial Cells
9. Global Cell Viability Assays Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Drug Discovery and Development 9.2. Basic Research 9.3. Stem Cell Research 9.4. Clinical and Diagnostic Applications 9.5. Other Applications
10. Global Cell Viability Assays Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Pharmaceutical & Biotechnology Companies 10.2. Academic & Research Institutes 10.3. Hospital & Diagnostic Laboratories 10.4. Other End Users
11. North America Cell Viability Assays Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028
12. Latin America Cell Viability Assays Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028
13. Europe Cell Viability Assays Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028
14. Asia Pacific Cell Viability Assays Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. Thermo Fisher Scientific 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Merck KGaA 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Bio-Rad Laboratories 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. GE Healthcare 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Danaher Corporation 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Becton, Dickinson and Company 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Promega Corporation 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Biotium 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Abcam PLC 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Creative Bioarray 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Biotek Instruments 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Perkinelmer 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview
18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics